ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,396,975, issued on Aug. 26, was assigned to Oncopeptides AB (Stockholm).
"Treatment of al amyloidosis with melflufen" was invented by Jakob Lindberg (Stockholm).
According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides melflufen, or a salt thereof, or a pharmaceutical formulation comprising melflufen, or a salt thereof, for use in the treatment and/or prophylaxis of immunoglobulin light chain (AL) amyloidosis. The invention also provides dosage regimens and kits that find utility in the treatment and/or prophylaxis of AL amyloidosis, and methods for the treatment and/or prophylaxis of AL amyloidosis, and uses of melflufen, or a salt thereof, ...